Access to Prescription Digital Therapeutics Act of 2022

Hozzl · 2024-03-11T21:44:12Z

Explore the details of Senate Bill 3791 Access to Prescription Digital Therapeutics Act of 2022 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

3/11/2024, 9:44 PM

Congressional Summary of S 3791

Access to Prescription Digital Therapeutics Act of 2022

This bill provides for Medicare and Medicaid coverage of prescription digital therapeutics (i.e., software applications that are used to prevent, manage, or treat medical conditions). The Centers for Medicare & Medicaid Services must establish a Medicare payment methodology for payments to manufacturers that takes into account certain factors (e.g., ongoing use); manufacturers must report specified information about private payors, subject to civil penalties.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 3791

Bill S 3791 is currently in the status of Bill Introduced since March 10, 2022. Bill S 3791 was introduced during Congress 117 and was introduced to the Senate on March 10, 2022. Bill S 3791's most recent activity was Read twice and referred to the Committee on Finance. as of March 10, 2022

Bipartisan Support of Bill S 3791

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 3791

Primary Policy Focus

Health

Potential Impact Areas

- Business records

- Civil actions and liability

- Computers and information technology

- Digital media

- Health care costs and insurance

- Internet, web applications, social media

- Medicaid

- Medicare

- Prescription drugs

Alternate Title(s) of Bill S 3791

Access to Prescription Digital Therapeutics Act of 2022

A bill to amend titles XVIII and XIX of the Social Security Act to provide for coverage of prescription digital therapeutics under such titles, and for other purposes.